These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20046703)

  • 1. Strategies for enhanced drug delivery to the central nervous system.
    Dwibhashyam VS; Nagappa AN
    Indian J Pharm Sci; 2008; 70(2):145-53. PubMed ID: 20046703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
    Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
    Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders.
    Koehn LM
    Neural Regen Res; 2020 Jul; 15(7):1235-1242. PubMed ID: 31960802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
    Löscher W; Potschka H
    Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The barrier and interface mechanisms of the brain barrier, and brain drug delivery.
    Zhang S; Gan L; Cao F; Wang H; Gong P; Ma C; Ren L; Lin Y; Lin X
    Brain Res Bull; 2022 Nov; 190():69-83. PubMed ID: 36162603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain.
    Sugiyama Y; Kusuhara H; Suzuki H
    J Control Release; 1999 Nov; 62(1-2):179-86. PubMed ID: 10518649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery to the central nervous system: a review.
    Misra A; Ganesh S; Shahiwala A; Shah SP
    J Pharm Pharm Sci; 2003; 6(2):252-73. PubMed ID: 12935438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Membrane Transporters and Their Regulatory Mechanisms at the Brain and Retinal Barriers to Establish Therapies for Refractory Central Nervous System Diseases].
    Akanuma SI
    Yakugaku Zasshi; 2020; 140(10):1235-1242. PubMed ID: 32999202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and physiological factors influencing CNS delivery upon intranasal administration.
    Vyas TK; Tiwari SB; Amiji MM
    Crit Rev Ther Drug Carrier Syst; 2006; 23(4):319-47. PubMed ID: 17341201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.
    Miller DS; Bauer B; Hartz AM
    Pharmacol Rev; 2008 Jun; 60(2):196-209. PubMed ID: 18560012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface].
    Tachikawa M; Uchida Y; Terasaki T
    Brain Nerve; 2013 Feb; 65(2):121-36. PubMed ID: 23399670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane transporter proteins: a challenge for CNS drug development.
    Girardin F
    Dialogues Clin Neurosci; 2006; 8(3):311-21. PubMed ID: 17117613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.
    Chan GN; Evans RA; Banks DB; Mesev EV; Miller DS; Cannon RE
    Neurosci Lett; 2017 Feb; 639():103-113. PubMed ID: 28011392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug efflux transporters in the CNS.
    Sun H; Dai H; Shaik N; Elmquist WF
    Adv Drug Deliv Rev; 2003 Jan; 55(1):83-105. PubMed ID: 12535575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
    Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
    Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches to enhance CNS delivery of drugs across the brain barriers.
    Lu CT; Zhao YZ; Wong HL; Cai J; Peng L; Tian XQ
    Int J Nanomedicine; 2014; 9():2241-57. PubMed ID: 24872687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier.
    Pathan N; Shende P
    J Control Release; 2021 Jul; 335():398-407. PubMed ID: 34087246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic Cation Transporter (OCT/OCTN) Expression at Brain Barrier Sites: Focus on CNS Drug Delivery.
    Betterton RD; Davis TP; Ronaldson PT
    Handb Exp Pharmacol; 2021; 266():301-328. PubMed ID: 33674914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.